Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

LESSONS LEARNED: Radiotherapy plus anti–PD‐1 antibody as first‐line therapy is safe and feasible in locally advanced esophageal squamous cell carcinoma (ESCC). Tumor‐infiltrating and peripheral lymphocytes were associated with patient survival. Further studies combining chemoradiotherapy with immuno...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wencheng, Yan, Cihui, Gao, Xuan, Li, Xiaoxia, Cao, Fuliang, Zhao, Gang, Zhao, Jingjing, Er, Puchun, Zhang, Tian, Chen, Xi, Wang, Yuwen, Jiang, Yao, Wang, Quanren, Zhang, Baozhong, Qian, Dong, Wang, Jun, Zhou, Dejun, Ren, Xiubao, Yu, Zhentao, Zhao, Lujun, Yuan, Zhiyong, Wang, Ping, Pang, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265339/
https://www.ncbi.nlm.nih.gov/pubmed/33893689
http://dx.doi.org/10.1002/onco.13797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8265339/
https://www.ncbi.nlm.nih.gov/pubmed/33893689
http://dx.doi.org/10.1002/onco.13797

Ejemplares similares